enGene Inc. Warrants (ENGNW)
NASDAQ: ENGNW
· Real-Time Price · USD
0.71
-0.02 (-2.74%)
At close: May 23, 2025, 9:31 AM
0.71
0.00%
Pre-market: May 23, 2025, 09:31 AM EDT
Company Description
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs.
Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.
The company was founded in 2023 and is based in Saint-Laurent, Canada.
enGene Inc. Warrants
| Country | CA |
| IPO Date | n/a |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 56 |
| CEO | Ronald H. W. Cooper |
Contact Details
Address: No Address available Montreal, CA | |
| Website | https://www.engene.com |
Stock Details
| Ticker Symbol | ENGNW |
| Exchange | NASDAQ |
| Fiscal Year | n/a |
| Reporting Currency | USD |
| CIK Code | 0001980845 |
| CUSIP Number | n/a |
| ISIN Number | n/a |
| Employer ID | 00-0000000 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Ronald H. W. Cooper | President, Chief Executive Officer & Director |
| David Ryan Daws | Chief Financial Officer & Head of Business Development |
| Joan Connolly | Chief Technology Officer |
| Lee G. Giguere | Chief Legal Officer & Corporate Secretary |
| Dr. Alexander Nichols Ph.D. | Chief Strategy & Operations Officer |
| Dr. Anthony T. Cheung Ph.D. | Co-Founder & Chief Scientific Officer |
| Dr. Raj S. Pruthi F.A.C.S., M.D., M.H.A. | Chief Medical Officer |
| John C. Brown D.Sc., FRSC, Ph.D. | Co-Founder and Member of Scientific Advisory Board |
| Matthew Boyd | Senior Vice President of Regulatory Affairs |
| Tara Place M.B.A. | Senior Vice President of Human Resources |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 09, 2025 | ARS | Filing |
| May 09, 2025 | DEF 14A | Filing |
| Mar 10, 2025 | S-8 | Filing |
| Mar 10, 2025 | 10-Q | Quarterly Report |
| Mar 10, 2025 | 8-K | Current Report |
| Feb 20, 2025 | 10-K/A | [Amend] Annual Report |
| Feb 14, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| Feb 14, 2025 | SCHEDULE 13G | Filing |
| Feb 14, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| Feb 14, 2025 | SCHEDULE 13G/A | [Amend] Filing |